Eli Lilly's strong momentum in blockbuster therapies and promising pipeline signals future growth, but competition and ...

Scientists are testing an experimental anti-amyloid antibody in people expected to develop early-onset Alzheimer's.

Monoclonal antibodies have emerged as a promising approach in the fight against Alzheimer's disease, offering hope for ...

Eli Lilly (LLY) investors should expect fireworks this week as the pharma giant prepares to drop its bombshell Q4 2024 ...

Eli Lilly's innovative culture and strong financial ... Lilly is developing a new Alzheimer’s drug (Kisunla/donanemab) that could become a major blockbuster, especially since few treatment ...

Nico Chen’s rating is based on a combination of factors that highlight Eli Lilly & Co’s promising ... for diabetes and weight loss, and Donanemab for Alzheimer’s disease.

We maintain Eli Lilly’s High Uncertainty Rating ... including level of insurance coverage and pricing. Alzheimer’s drug donanemab holds the potential to become another major new drug, but ...